NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: ABVC BioPharma's Licensing Partnership with OncoX BioPharma and Business Model
TL;DR
ABVC's licensing model with OncoX provides investors competitive advantage through predictable cash flow and future 5% royalties on up to $55 million in sales.
ABVC's three-tier business model generates short-term licensing payments and long-term royalty revenue by transforming R&D assets into scalable, asset-light partnerships.
This partnership advances plant-based cancer therapies that could improve treatment options for breast cancer, lung cancer, and other serious conditions worldwide.
OncoX develops cancer treatments from maitake mushroom extract while building a global biotechnology network connecting US and Asian markets.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma has received an additional $100,000 licensing payment from OncoX BioPharma, marking the fifth licensing payment in 2025 and bringing total payments to $695,950 under their existing agreement.
This payment demonstrates cash-flow visibility and consistent milestone execution, advancing ABVC's multi-partner licensing strategy and supporting their transition to an asset-light, cash-visible international licensing platform.
OncoX BioPharma is a U.S.-based biotechnology company specializing in developing plant-derived oncology therapeutics, with a lead candidate derived from maitake mushroom extract targeting multiple cancers.
OncoX's lead candidate has shown potential in treating triple-negative breast cancer, non-small-cell lung cancer, pancreatic cancer, and myelodysplastic syndrome (MDS).
ABVC's model includes short-term licensing payments (0-12 months), mid-term milestones, and long-term 5% royalties on net sales up to $55 million, creating sustainable, high-profit-margin recurring income.
ABVC will receive 5% royalties on net sales up to cumulative $55 million, creating a sustainable, high-profit-margin recurring income stream for the company.
Based on consolidated data across all licensing partners, ABVC's total contractual cash revenue pool has the potential to reach up to $14.25 million, with $2.14 million received as of October 2025.
This collaboration illustrates the effectiveness of ABVC's licensing-driven business model in transforming R&D assets into recurring value creation, helping transition from a research-focused company to an asset-light licensing platform.
OncoX is actively expanding into cancer-supportive care and preventative health through proprietary natural ingredients, and has acquired the Lycogen® extraction platform to enter adjacent fields including preventative medicine.
OncoX collaborates with several leading Japanese biomedical companies and academic institutions to co-develop Precision Gene-Oriented Therapies and Anti-Fibrosis Technologies, forming a biotechnology network connecting U.S. and Asian markets.
Curated from NewMediaWire
